Search clinical trials for: Placebo ASP8062

Total 53472 results

Astellas Pharma Europe B.V.

Completed

A Study of ASP8302 in Participants With Underactive Bladder

Underactive Bladder

Japan, Poland, Germany, Netherlands, Slovakia, United Kingdom
Astellas Pharma Inc

Completed

ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects

Healthy Subjects

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Healthy Subjects | Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease (CKD) | Pharmacokinetics of ASP8232 | Pharmacodynamics of ASP8232

Bulgaria, Moldova, Republic of, Romania
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects (MAD)

Healthy Volunteers | Pharmacokinetics of ASP7962

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans

Tolerability | Safety | Pharmacokinetics of ASP7962

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Peanut Allergy

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (ALBUM)

Type 2 Diabetes | Chronic Kidney Disease

Spain, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Advanced Solid Tumors

United States
Astellas Pharma Inc

Completed

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS

United States
Astellas Pharma Inc

Completed

Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Solid Tumor

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

Healthy Volunteers

United States
Sanofi

Completed

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Sarcoma

Belgium, Hungary, United States, Brazil, France, India, Italy, Serbia, Spain, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Peanut Allergy

United States
Astellas Pharma Global Development, Inc.
National Institute on Drug Abuse (NIDA)

Completed

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Opioid Use Disorder

United States
Sanofi

Completed

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer (DISRUPT)

Non-small Cell Lung Cancer

France, Romania, Poland, Croatia, Korea, Republic of, Italy, Chile, United States, Australia, Germany, Russian Federation, Serbia, Ukraine
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Opioid Use Disorder
Astellas Pharma Global Development, Inc.

Not yet recruiting

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

B-cell Lymphoma
Astellas Pharma Inc

Completed

Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects

Healthy Volunteers

Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors

Solid Tumor

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Fibromyalgia

United States
Sanofi

Completed

AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

Neoplasms

France, Italy, Switzerland
Astellas Pharma Global Development, Inc.
National Institute on Drug Abuse (NIDA)

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

Opioid Use Disorder

United States
Sanofi

Completed

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

Neoplasms, Malignant

Belgium
National Institute on Alcohol Abuse and Alcoholism...
Astellas Pharma Inc

Completed

Human Laboratory Study of ASP8062 for Alcohol Use Disorder

Alcohol Drinking | Alcohol Use Disorder | Alcohol Use Disorder (AUD)

United States
Astellas Pharma Global Development, Inc.

Terminated

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy (PDPN)

United States
Astellas Pharma Inc

Recruiting

A Study of ASP3082 in Adults With Previously Treated Solid Tumors

Solid Tumor

United States, Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Neoplasms, Malignant

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI)

Diabetes Mellitus | Diabetic Macular Edema

United States
Sanofi

Completed

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel (OPSALIN)

Ovarian Cancer Recurrent

Belgium, Russian Federation, Poland, Spain, Czech Republic, United States, France, Germany, Italy, Ukraine
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP1012 in Adults With Solid Tumors

Solid Tumor

United States
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

Advanced Neoplastic Disease
Sanofi

Completed

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Neoplasms, Malignant

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee (OAK)

Osteoarthritis of the Knee | Chronic Lower Back Pain

Belgium, Czechia, Germany, Hungary, Spain, United Kingdom
Sanofi

Completed

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Neoplasms, Malignant

France, United Kingdom, Italy
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Chinese University of Hong Kong

Recruiting

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

COVID-19

Hong Kong
National University of Malaysia
Malaysia Palm Oil Board

Unknown

Supplementation of Oil Palm Phenolics to Healthy Participants (SPIRAL)

Cardiovascular Diseases | Hypercholesterolemia | Hyperlipidemias

Malaysia
Astellas Pharma Global Development, Inc.
Yale University

Completed

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

Healthy Volunteers | Pharmacokinetics of ASP3662 | Displacement of Radiotracer

United States
Gladwin, Mark, MD
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age (Nitrite)

Sedentary Lifestyle | Frailty | Aging

United States
Mersin University

Completed

The Effect of Post-Cesarean Section Acupressure on the Severity of Pain and First Mobilization Distance (Acupress)

Pain | Mobilization

Turkey
University of South Carolina
U.S. Army Medical Research and Development Command

Completed

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

Seaweed Associated Changes in Healthy Subjects

United States
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Active, not recruiting

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)

Critical Limb Ischemia

Poland
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)

Heart Failure

Poland
LEO Pharma

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Atopic Dermatitis

United States, Belgium, Canada, Australia, France, Germany, Japan, Netherlands, Poland, United Kingdom
Guang'anmen Hospital of China Academy of Chinese...
Hubei Hospital of Traditional Chinese Medicine; Hebei Yiling Hospital; The First... and other collaborators

Unknown

The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.

Type 2 Diabetes Mellitus

3

Subscribe